TransMedics Group, Inc.

TMDX Healthcare Medical Devices

TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

70.78 5.74 −7.50%
Market cap
$2.7B
P/E
16.0×
Fwd P/E
34.1×
Dividend yield
—
F-score
7/9
Altman Z
5.32
Beneish M
−1.32
Dividend safety
n/a

TransMedics Group, Inc. (TMDX) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, TransMedics Group, Inc. (TMDX) trades at a P/E ratio of 16.0×. Over the past ten years it has ranged from 0.0× (June 2024) to 2,201× (August 2024); the current reading is higher than 71% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 21.8× (62.59%)
FY2024 58.3× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 15.0× (23.97%)
Mar 2026 19.8× (9.35%)
Dec 2025 21.8× (47.54%)
Sep 2025 41.6× (34.26%)
30 more quarters

Against its own ten years

Low 0.0× High 2,201×
Ten-year median 0.0×
Current reading's percentile 71

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TMDX